Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vitargin is a metabolic and hepatoprotective combination product developed and marketed by the Ukrainian company Ecopharm. It is formulated with two primary active ingredients: L-arginine and betaine. L-arginine is a semi-essential amino acid that acts as a substrate for nitric oxide synthase, leading to the production of nitric oxide which promotes vasodilation and improves microcirculation. Additionally, L-arginine is a key component of the urea cycle, aiding in the detoxification of ammonia. Betaine (trimethylglycine) serves as a methyl donor in the conversion of homocysteine to methionine and acts as an osmolyte, protecting hepatocytes from osmotic stress and supporting lipid metabolism to prevent or reduce hepatic steatosis. Vitargin is typically used to support liver function in conditions such as hepatitis, fatty liver disease (steatosis), and during recovery from physical exhaustion or toxic insults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vitargin.